CLINDAMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H33ClN2O5S
Molecular Weight	424.983
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O)[C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl

InChI

InChIKey=KDLRVYVGXIQJDK-AWPVFWJPSA-N

InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C18H33ClN2O5S
Molecular Weight	424.983
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm

Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial 70S ribosome 179 Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12860123	Inhibitor 8228
Bacterial 70S ribosome 179 Target ID: CHEMBL2363135 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Inhibitor 8228

Conditions

Condition	Modality	Highest Phase	Product
Serious soft tissue infections 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8360	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 4.4928E9
Serious respiratory tract infections 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8360	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 4.4928E9
Serious skin infections 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8360	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 4.4928E9
Sepsis 71 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8360	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 4.4928E9
Intra-abdominal infections 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8360	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 4.4928E9
Infections of the female pelvis 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8360	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 4.4928E9
Infections of the genital tract 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Curative	Approved 8360	CLEOCIN HYDROCHLORIDE Approved Use Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 4.4928E9
Acne vulgaris 34 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf	Curative	Approved 8360	CLEOCIN T Approved Use Clindamycin Phosphate is indicated in the treatment of acne vulgaris. Launch Date 3.31862409E11
Lower respiratory tract infections 51 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050441s053,050639s015lbl.pdf	Curative	Approved 8360	CLEOCIN PHOSPHATE Approved Use Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Launch Date 8.6745596E10
Skin and skin structure infections 80 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8360	CLEOCIN PHOSPHATE Approved Use Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Launch Date 8.6745596E10
Gynecological infections 8 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8360	CLEOCIN PHOSPHATE Approved Use Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Launch Date 8.6745596E10
Intra-abdominal infections 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8360	CLEOCIN PHOSPHATE Approved Use Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Launch Date 8.6745596E10
Sepsis 71 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8360	CLEOCIN PHOSPHATE Approved Use Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Launch Date 8.6745596E10
Bone and joint infections 27 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf	Curative	Approved 8360	CLEOCIN PHOSPHATE Approved Use Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. Launch Date 8.6745596E10

C_max

Value	Dose	Co-administered	Analyte	Population
3.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.92 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050803Orig1s000ClinPharmR.pdf	0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
12.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
13.54 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/050803Orig1s000ClinPharmR.pdf	0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		CLINDAMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11689755 Page: p.571	unhealthy, 16 - 51 n = 79 Health Status: unhealthy Condition: Bacterial Vaginosis Age Group: 16 - 51 Sex: F Population Size: 79 Sources: https://pubmed.ncbi.nlm.nih.gov/11689755 Page: p.571	Disc. AE: Vaginal pain or burning... AEs leading to discontinuation/dose reduction: Vaginal pain or burning (1.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/11689755 Page: p.571
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Anaphylactic shock Hypersensitivity reaction (severe) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Anaphylactic shock Hypersensitivity reaction (severe) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Anaphylactic shock Hypersensitivity reaction (severe) Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf Page: p.1	Disc. AE: Diarrhea, Clostridium difficile, Reaction skin... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Reaction skin (severe) Toxic epidermal necrolysis (grade 3-5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Vaginal pain or burning	1.2% Disc. AE	5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11689755 Page: p.571	unhealthy, 16 - 51 n = 79 Health Status: unhealthy Condition: Bacterial Vaginosis Age Group: 16 - 51 Sex: F Population Size: 79 Sources: https://pubmed.ncbi.nlm.nih.gov/11689755 Page: p.571
Anaphylactic shock	Disc. AE	1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Diarrhea, Clostridium difficile	Disc. AE	1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Hypersensitivity reaction	severe Disc. AE	1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Anaphylactic shock	Disc. AE	300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Diarrhea, Clostridium difficile	Disc. AE	300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Hypersensitivity reaction	severe Disc. AE	300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Anaphylactic shock	Disc. AE	300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Diarrhea, Clostridium difficile	Disc. AE	300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Hypersensitivity reaction	severe Disc. AE	300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display
Diarrhea, Clostridium difficile	Disc. AE	450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf Page: p.1
Toxic epidermal necrolysis	grade 3-5 Disc. AE	450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf Page: p.1
Reaction skin	severe Disc. AE	450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inhibitor 1579	inhibitor 1752	inhibitor 1837

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2C19 1463 CYP2E1 876	CYP1A2 1032 CYP2A6 523 CYP2B6 660 CYP2C8 688 CYP2C18 139 CYP2C19 985 CYP2E1 648 CYP3A5 391 CYP4A11 102

Drug as perpetrator

Target	Modality	Activity
CYP3A4 1909	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 1.0	moderate [Inhibition 100 uM]
CYP1A2 1673	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no
CYP2C19 1537	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no
CYP2C9 1803	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no
CYP2D6 1875	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no
CYP2E1 964	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050162s098s099lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	major	likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050162s098s099lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0
CYP3A5 391	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050162s098s099lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	minor	likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050162s098s099lbl.pdf#page=3; https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0
CYP1A2 1032	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2A6 523	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2B6 660	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2C18 139	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2C19 985	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2C8 688	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP2E1 648	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined
CYP4A11 102	substrate 3326 Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0	not determined

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3745	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3745
eMolecules	2749645	https://www.emolecules.com/cgi-bin/more?vid=2749645

PubMed

Title	Date	PubMed
Superantigen antagonist peptides.	2001	11299061
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia.	2001 Apr	11399017
Clinical features of patients with invasive Eikenella corrodens infections and microbiological characteristics of the causative isolates.	2001 Apr	11399011
Chronic granulomatous disease: a case report.	2001 Apr	11393130
[The latest trend of PRSP infection].	2001 Apr	11304999
Severe babesiosis in Long Island: review of 34 cases and their complications.	2001 Apr 15	11283800
Laparoscopic management of adnexal masses.	2001 Apr-Jun	11394427
Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.	2001 Feb	11251569
Anti-anaerobic activity of antibacterial agents.	2001 Feb	11178339
Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections.	2001 Feb	11169133
Two cases of diskitis attributable to anaerobic bacteria in children.	2001 Feb	11158500
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study.	2001 Feb	11157911
[Guidelines for antibiotic prophylaxis of bacterial endocarditis in patients undergoing dental therapy].	2001 Jan	11293977
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France.	2001 Jan	11245328
New uses of older antibiotics.	2001 Jan	11190348
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat.	2001 Jan 1	11149716
The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product.	2001 Jan-Feb	11281433
Bacteroides fragilis-induced intra-abdominal abscess in an experimental model treated with telithromycin (HMR 3647).	2001 Jan-Feb	11125232
Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents.	2001 Jul	11453902
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.	2001 Jul	11418523
Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads.	2001 Jul	11418521
Cutaneous botryomycosis of the cervicofacial region.	2001 Jul	11400249
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.	2001 Jun	11455504
The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea.	2001 Jun	11455497
Transfusion-transmitted babesiosis in Ontario: first reported case in Canada.	2001 Jun 12	11450217
Infection of hamsters with epidemiologically important strains of Clostridium difficile.	2001 Jun 15	11372028
A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.	2001 Jun 25	11427101
Antibiotic susceptibility of Clostridium difficile isolates from adult patients at two Jamaican hospitals. Clinical and epidemiological implications.	2001 Mar	11398289
Prevalence and phenotypes of erythromycin-resistant Streptococcus pneumoniae in Shanghai, China.	2001 Mar	11337187
Persistence of Plasmodium falciparum in the placenta after apparently effective quinidine/clindamycin therapy.	2001 Mar	11324359
[The therapeutic approach to necrotizing fasciitis].	2001 Mar	11319371
[Cellulitis and necrotizing fasciitis: microbiology and pathogenesis].	2001 Mar	11319369
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America.	2001 Mar	11318814
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.	2001 Mar	11318076
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.	2001 Mar	11315521
Antibiotic-resistant bacteria in pediatric chronic sinusitis.	2001 Mar	11303824
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children.	2001 Mar	11282264
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.	2001 Mar 30	11316995
[Dermo-hypodermitis and necrotizing fasciitis].	2001 Mar 31	11345864
Effect of clindamycin therapy on phagocytic and oxidative activity profiles of spleen mononuclear cells in Babesia rodhaini-infected mice.	2001 May	11411505
Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial.	2001 May	11339909
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.	2001 May	11337227
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.	2001 May 15	11320449
Sensitive and specific determination of clindamycin in human serum and bone tissue applying liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry.	2001 May 5	11393698
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.	2001 May-Jun	11448565
Isolation and antimicrobial susceptibility testing of fecal strains of the archaeon Methanobrevibacter smithii.	2001 May-Jun	11306786
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.	2001 Spring	11310802
Erythromycin and amoxicillin?	2001 Winter	11324196

Patents

Sample Use Guides

In Vivo Use Guide

150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).

Route of Administration: Oral

In Vitro Use Guide

MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).

Substance Class	Chemical Created by `admin` on `Thu Jul 06 21:25:09 UTC 2023` Edited by `admin` on `Thu Jul 06 21:25:09 UTC 2023`
Record UNII	3U02EL437C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLINDAMYCIN

Official Name

English

U-21,251

Code

English

clindamycin [INN]

Common Name

English

U-21251

Code

English

CLINDAMYCIN [MART.]

Common Name

English

CLINDAMYCIN [USAN]

Common Name

English

CLINDAMYCIN [GREEN BOOK]

Common Name

English

Clindamycin [WHO-DD]

Common Name

English

METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(1-METHYL-TRANS-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE

Common Name

English

7(S)-CHLORO-7-DEOXYLINCOMYCIN

Common Name

English

CLINDAMYCIN [VANDF]

Common Name

English

CLINDAMYCIN PHOSPHATE IMPURITY E [EP IMPURITY]

Common Name

English

CLINDAMYCIN [HSDB]

Common Name

English

L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, (2S-TRANS)-

Common Name

English

CLINDAMYCIN [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QD10AF01